Industry leading drug compounder is the first 503B to use KitCheck’s tunnel technology and registry systemSeptember 09, 2020 09:00 AM Eastern Daylight Time
WASHINGTON–(BUSINESS WIRE)– Bluesight , the leader in automated and intelligent medication management solutions, today announced that it has signed an agreement with SCA Pharma that allows SCA to add an embedded RFID tag to all of its products. SCA Pharma, an FDA registered 503B entity, will be the first 503B partner to utilize KitCheck’s tunnel association technology and register all drugs in the cloud-based registry.
SCA Pharma’s extensive product catalog will be combined with KitCheck’s advancements in RFID tagging technology to present dynamic products to SCA customers.
By utilizing KitCheck technology, SCA Pharma will continue to deliver on its mission to offer hospitals solutions that improve the efficiency and accuracy of OR medication tracking processes. SCA Pharma’s extensive product catalog will be combined with KitCheck’s advancements in RFID tagging technology to present dynamic products to SCA customers. All SCA Pharma products will now be “ready to go” right out of the box, and the embedded RFID tag will save room in OR trays, allowing for more ease of use.
“Over the years we’ve been working together, KitCheck’s technology has allowed us to provide customers with stronger, safer products,” said Milton Boyer, CEO of SCA Pharma. “With the implementation of RFID tracking tags on all SCA Pharma products, our customers will have even more confidence in their overall OR medication tracking processes and can be sure that any potential diversion attempts will be halted at the first sign of abnormality.”
KitCheck is a leader in RFID-based medication inventory tracking and automated tray processing in use at more than 500 hospitals in the U.S. and Canada, and the company recently celebrated its 100 millionth RFID-tracked medication. SCA Pharma, a leader in the field of sterile compounding, is certified by DoseID – the first-of-its-kind RFID certification body for the pharmaceutical space – and will be the first 503B partner to utilize KitCheck’s tunnel association technology, which registers important item level data for each unit of medication at the point of production and creates a record for that product’s dynamic lifecycle. Both KitCheck and SCA are members of DoseID.
“As hospitals navigate this busy, uncertain time, it’s become increasingly important for them to acquire medication intelligence capabilities,” said Kevin MacDonald, CEO and co-founder of Bluesight. “SCA Pharma’s decision to upgrade their RFID tracking technology will continue to help hospitals keep their drugs safe, furthering KitCheck’s mission of diminishing the issue of drug diversion within the medical space and in our local communities.”
